The mean age of patients was 48.5 ± 9.0 years (range 38 to 50 years); 5/6 (83%) were female, 5/6 (83%) had stage IV NSCLC, three (50%) had mutations in EGFR and three (50%) had mutations in ALK. This evidence concerns the gene ALK and non-small cell lung carcinoma.